Evidence map›Paper›PMID 27558941›Full record

ArticleThe Journal of general virology2016

Functional characterization of hepatitis B virus core promoter mutants revealed transcriptional interference among co-terminal viral mRNAs.

Chaoyang Chen, Haodi Jia, Fei Zhang, Yanli Qin, Li Zong, Quan Yuan, Yongxiang Wang, Ningshao Xia, Jisu Li, Yumei Wen and 1 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of general virology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Chaoyang ChenKey Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
Haodi JiaKey Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
Fei ZhangKey Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
Yanli QinDepartment of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, PR China.
Li ZongKey Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
Quan YuanState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, PR China.
Yongxiang WangKey Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
Ningshao XiaState Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, PR China.
Jisu LiThe Liver Research Center, Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI, USA.
Yumei WenKey Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Fudan University, Shanghai, PR China.
Shuping TongThe Liver Research Center, Rhode Island Hospital, Warren Alpert School of Medicine, Brown University, Providence, RI, USA.
Fudan University · CNXiamen University · CNHuashan Hospital · CNRhode Island Hospital · US

Funding

Hepatitis B virus vaccine escape mutantsR01AI116639 · NIAID · RHODE ISLAND HOSPITAL · PI TONG, SHUPING · 2015 to 2019
$1.8M
Hepatitis B virus transcriptional interference and liver cancer-related mutationsR21AI113394 · NIAID · RHODE ISLAND HOSPITAL · PI TONG, SHUPING · 2015 to 2016
$443k
Hepatitis B virus genotypes B and CR21AI103648 · NIAID · RHODE ISLAND HOSPITAL · PI TONG, SHUPING · 2013 to 2014
$437k
Control of HBV replication at the step of core and P protein translationR21AI107618 · NIAID · RHODE ISLAND HOSPITAL · PI LI, JISU · 2013 to 2014
$423k
NIAID NIH HHS R01 AI116639NIAID NIH HHS R21 AI103648NIAID NIH HHS R21 AI107618NIAID NIH HHS R21 AI113394
6 · The paper itself

Abstract

Hepatitis B virus (HBV) has a 3.2 kb circular DNA genome. It employs four promoters in conjunction with a single polyadenylation signal to generate 3.5, 2.4, 2.1 and 0.7 kb co-terminal RNAs. The 3.5 kb RNA is subdivided into the precore RNA for e-antigen expression and pregenomic RNA for genome replication. When introduced to a genotype A clone, several core promoter mutations markedly enhanced HBV genome replication, but suppressed e-antigen expression through up-regulation of pregenomic RNA at the expense of precore RNA. In this study, we found such mutations also diminished envelope proteins and hepatitis B surface antigen, products of the 2.1 and 2.4 kb subgenomic RNAs. Indeed, Northern blot analysis revealed overall increase in 3.5 kb RNA, but reduction in all subgenomic RNAs. To validate transcriptional interference, we subcloned 1.1×, 0.7× and 0.6× HBV genome, respectively, to a vector with or without a cytomegalovirus (CMV) promoter at the 5' end, so as to produce the pregenomic RNA, 2.4 kb RNA, and 2.1 kb RNA in large excess or not at all. Parallel transfection of the three pairs of constructs into a human hepatoma cell line confirmed the ability of pregenomic RNA to suppress all subgenomic transcripts and established the ability of the 2.4 and 2.1 kb RNAs to suppress the 0.7 kb RNA. Consistent with our findings, pregenomic RNA of the related duck HBV has been reported to interfere with transcription of the subgenomic RNAs. Transcriptional interference might explain why HBV produces so little 0.7 kb RNA and HBx protein despite a strong X promoter.

Indexed as

Promoter Regions, GeneticGene Expression Regulation, ViralHepatitis BHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusHumansRNA InterferenceRNA, MessengerRNA, ViralTranscription, GeneticHepatitis B Core AntigensHepatitis B e AntigensHepatitis B Surface AntigensRNA, MessengerRNA, Viral

Identifiers

PMID27558941
PMCPMC6542254
OpenAlexW2509188515

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.